Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2023

Open Access 03-07-2023 | Ketoacidosis | Case report

Unexpected cause of recurrent diabetic ketoacidosis in type 1 diabetes: a case report

Authors: Rabia Khalid Alduraibi, Yosef Fahad Altowayan, Bader Tha’ar AlMharwal

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Abstract

Background

Gastrointestinal (GI) symptoms are commonly observed in patients with diabetic ketoacidosis (DKA), which usually resolves completely with therapy. However, GI symptoms can persist after DKA resolves, which can pose diagnostic and management challenges for physicians, especially when dealing with an exceptional diagnosis such as cannabinoid hyperemesis syndrome (CHS).

Case presentation

In this case report, we present a patient with type 1 diabetes who had been treated for DKA 6 times in the past year and was eventually diagnosed with CHS.

Conclusion

In conclusion, this case demonstrates that a presumptive and incorrect diagnosis can mislead physicians, especially when dealing with challenging diagnoses. Therefore, patients with type 1 diabetes with unusual presentations, such as unexpectedly high pH and bicarbonate levels, with hyperglycemic ketosis should be screened for illicit drug use, especially cannabis.
Literature
1.
go back to reference United Nations. World Drug Report 2019; Cannabis and hallucinogens. 2019. Retrieved from https://wdr.unodc. org/wdr2019/en/cannabis-and-hallucinogens.html. United Nations. World Drug Report 2019; Cannabis and hallucinogens. 2019. Retrieved from https://​wdr.​unodc. org/wdr2019/en/cannabis-and-hallucinogens.html.
2.
go back to reference Alshmrani S. 7% of Saudis are drug users. Saudi Arabia: Al-Hayat; Newspaper 2017. Alshmrani S. 7% of Saudis are drug users. Saudi Arabia: Al-Hayat; Newspaper 2017.
3.
go back to reference Al-Musa HM, Al-Montashri SDS. Substance abuse among male secondary school students in Abha city, Saudi Arabia: prevalence and associated factors. Biomed Res. 2016;27:1364–73. Al-Musa HM, Al-Montashri SDS. Substance abuse among male secondary school students in Abha city, Saudi Arabia: prevalence and associated factors. Biomed Res. 2016;27:1364–73.
4.
go back to reference Ibrahim Y, Hussain SM, Alnasser S, Almohandes H, Sarhandi I. Patterns and sociodemographic characteristics of substance abuse in Al Qassim, Saudi Arabia: a retrospective study at a psychiatric rehabilitation center. Ann Saudi Med. 2018;38(5):319–25.CrossRefPubMedPubMedCentral Ibrahim Y, Hussain SM, Alnasser S, Almohandes H, Sarhandi I. Patterns and sociodemographic characteristics of substance abuse in Al Qassim, Saudi Arabia: a retrospective study at a psychiatric rehabilitation center. Ann Saudi Med. 2018;38(5):319–25.CrossRefPubMedPubMedCentral
5.
go back to reference Akturk HK, Taylor DD, Camsari UM, Rewers A, Kinney GL, Shah VN. Association between cannabis use and risk for diabetic ketoacidosis in adults with type 1 diabetes. JAMA Intern Med. 2019;179:115–8.CrossRefPubMed Akturk HK, Taylor DD, Camsari UM, Rewers A, Kinney GL, Shah VN. Association between cannabis use and risk for diabetic ketoacidosis in adults with type 1 diabetes. JAMA Intern Med. 2019;179:115–8.CrossRefPubMed
6.
go back to reference Kinney GL, Akturk HK, Taylor DD, Foster NC, Shah VN. Cannabis use is associated with increased risk for diabetic ketoacidosis in adults with type 1 diabetes: findings from the T1D Exchange Clinic Registry. Diabetes Care. 2020;43:247–9.CrossRefPubMed Kinney GL, Akturk HK, Taylor DD, Foster NC, Shah VN. Cannabis use is associated with increased risk for diabetic ketoacidosis in adults with type 1 diabetes: findings from the T1D Exchange Clinic Registry. Diabetes Care. 2020;43:247–9.CrossRefPubMed
7.
go back to reference Camilleri M. Cannabinoids and gastrointestinal motility: pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterol Motil. 2018;30:e13370.CrossRefPubMedPubMedCentral Camilleri M. Cannabinoids and gastrointestinal motility: pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterol Motil. 2018;30:e13370.CrossRefPubMedPubMedCentral
8.
go back to reference Chocron Y, Zuber JP, Vaucher J. Cannabinoid hyperemesis syndrome. BMJ. 2019;19:366. Chocron Y, Zuber JP, Vaucher J. Cannabinoid hyperemesis syndrome. BMJ. 2019;19:366.
9.
go back to reference Zimmer DI, McCauley R, Konanki V, Dynako J, Zackariya N, Shariff F, Miller J, Binz S, Walsh M. Emergency department and radiological cost of delayed diagnosis of cannabinoid hyperemesis. J Addict. 2019;1:2019. Zimmer DI, McCauley R, Konanki V, Dynako J, Zackariya N, Shariff F, Miller J, Binz S, Walsh M. Emergency department and radiological cost of delayed diagnosis of cannabinoid hyperemesis. J Addict. 2019;1:2019.
10.
go back to reference Gallo T, Shah VN. An unusual cause of re- current diabetic ketoacidosis in type 1 diabetes. Am J Med. 2016;129:e139–40.CrossRefPubMed Gallo T, Shah VN. An unusual cause of re- current diabetic ketoacidosis in type 1 diabetes. Am J Med. 2016;129:e139–40.CrossRefPubMed
Metadata
Title
Unexpected cause of recurrent diabetic ketoacidosis in type 1 diabetes: a case report
Authors
Rabia Khalid Alduraibi
Yosef Fahad Altowayan
Bader Tha’ar AlMharwal
Publication date
03-07-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01394-3

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.